- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03889379
Albuterol and Immune Cell Composition
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Neuroblastoma is a cancer that typically affects the nerves of children. Sometimes the treatment required for neuroblastoma is an autologous stem cell transplant, where patients who are experiencing neuroblastoma will undergo an expansion of their blood system and collect their peripheral blood to later infuse back into them after chemotherapy and/or radiation. However, up to 14% of individuals experience complications with this procedure.
Research has shown that certain drugs that cause similar effects on the body to that of acute exercise can elicit a more favorable donation. However, these drugs are very costly. Albuterol, on the other hand, is a regularly used drug that may have a similar effect on the body as adrenaline and is used to treat individuals who are experiencing respiratory airway distress. The benefit of albuterol is that it can be administered through inhalation, further reducing patient burden.
The aim of this pilot study is to determine the effects of albuterol on the composition of immune cells in the bloodstream. Five healthy volunteers (age 21-44 years) will be recruited to participate in this study. Each participant will donate a 6ml blood sample before and during a 20-minute continuous albuterol nebulization through an IV catheter. During the last 10 minutes of the nebulization, participants will submit to another 6mL blood draw.
Tipo de estudo
Estágio
- Fase inicial 1
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85724
- University of Arizona Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Any gender
- 21-44 years of age
Exclusion Criteria:
- Subjects must not: be younger than 21 or older than 44 years of age
- Indicate a condition on the ACSM-AHA preexercise screening questionnaire indicating that physician approval is required prior to exercise
- current user of tobacco products or have quit within the previous 6-months
- body mass index of >30 kg/m2, or waist girth of >102cm for men and >88cm for women
- use over-the-counter medication known to affect the immune system (i.e. regular use of ibuprofen/aspirin, anti-histamines or beta-blockers)
- have chronic/debilitating arthritis
- have been bedridden in the past three months
- have common illness (i.e. colds) within the past 6-weeks
- have HIV
- have hepatitis
- have had a stroke
- have major affective disorder
- have any autoimmune disease
- have central or peripheral nervous disorders
- have blood vessel disease
- have cardiovascular disease (CVD)
- use of any prescription medication
- pregnancy or are breast-feeding
- asthma, emphysema, bronchitis, kidney disease; pheochromocytoma; diabetes; overactive thyroid
- history of severe anaphylactic reaction to an allergen
- or are scheduled to have surgery
- Individuals who pass the exclusion criteria detailed above but present with more than one of the following CVD risk factors will also be excluded from the study: family history of myocardial infarction, coronary revascularization, or sudden death before 55 years of age in father or other male first-degree relative or before 65 years of age in mother or other female first-degree relative; hypertension (systolic blood pressure of >140 mmHg or diastolic blood pressure >90 mmHg); dyslipidemia (total serum cholesterol of >200 mg/dl); pre-diabetes (fasting blood glucose of >100mg/dl but <126 mg/dl).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Effects of Albuterol on Immune Cell Composition
This is a single subject repeated measure experimental design with each participant acting as his/her own control.
|
Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quantification of NK Cells (CD3-/CD56+).
Prazo: One year
|
Investigators will collect a 6mL blood sample into EDTA anti-coagulant tubes before and during the last five minutes of an albuterol nebulization to assess the quantification in both absolute number and proportion of NK cells (CD3-/CD56+) using a MACSQuant flow cytometer and subsequent analysis on FlowLogic Software (v7.2.1).
The last five minutes of nebulization of blood sample will be directly compared to the pre nebulization blood sample in the same participants in the same research arm.
|
One year
|
|
Quantification of Gamma Delta T Cells (CD4-CD8-).
Prazo: One year
|
Investigators will collect a 6mL blood sample into EDTA anti-coagulant tubes before and during the last five minutes of an albuterol nebulization to assess the quantification in both absolute number and proportion of Gamma Delta T cells (CD3+/CD4-/CD8-) using a MACSQuant flow cytometer and subsequent analysis on FlowLogic Software (v7.2.1).
The last five minutes of nebulization of blood sample will be directly compared to the pre nebulization blood sample in the same participants in the same research arm.
|
One year
|
|
Quantification of Gamma T cell subsets (CD3+/CD4/CD8).
Prazo: One year
|
Investigators will collect a 6mL blood sample into EDTA anti-coagulant tubes before and during the last five minutes of an albuterol nebulization to assess the quantification in both absolute number and proportion of T-cell subsets (CD3+/CD4/CD8) using a MACSQuant flow cytometer and subsequent analysis on FlowLogic Software (v7.2.1).
The last five minutes of nebulization of blood sample will be directly compared to the pre nebulization blood sample in the same participants in the same research arm.
|
One year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Grace M Niemiro, PhD, University of Arizona
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Efeitos Fisiológicos das Drogas
- Agentes Adrenérgicos
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Agonistas Adrenérgicos
- Agentes broncodilatadores
- Agentes Antiasmáticos
- Agentes do Sistema Respiratório
- Agentes de Controle Reprodutivo
- Agonistas de Receptores Beta-2 Adrenérgicos
- Beta-Agonistas Adrenérgicos
- Tocolíticos
- Salbutamol
Outros números de identificação do estudo
- 181229451
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .